GSK Fires China R&D Chief for Misrepresenting Data
publication date: Jun 12, 2013
According to GlaxoSmithKline, a scientific paper published by members of its China R&D staff contained “misrepresentations.” The British biopharma has fired Jiangwu Zhang, the head of its China R&D operation, who was listed as one of the authors. The 2010 Nature Medicine article investigated the role of interleukin-7 in autoimmune diseases. As a result of the scandal, GSK has suspended Phase I tests of GSK2618960, an experimental medicine for multiple sclerosis that was based in part on the article’s early-stage research. More details....
Stock Symbol: (NYSE: GSK)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.